Response to Treatment With Rituximab in a Patient With Acquired von Willebrand Disease

Publication
Article
OncologyONCOLOGY Vol 16 No 3
Volume 16
Issue 3

The patient is a 58-year-old woman (AA genotype) who was found to have a prolonged activated partial thromboplastin time (aPTT) of 65.7 seconds during a preoperative evaluation for spinal stenosis surgery and mild rectal bleeding. Her aPTT test repeatedly remained abnormally prolonged. The patient had an aPTT mixing study that did not correct immediately or at 2 hours (56.4 seconds vs control 29.7 seconds). Her bleeding time was also abnormally prolonged at 11 minutes.

The patient is a 58-year-old woman (AA genotype) who was found to have aprolonged activated partial thromboplastin time (aPTT) of 65.7 seconds during apreoperative evaluation for spinal stenosis surgery and mild rectal bleeding.Her aPTT test repeatedly remained abnormally prolonged. The patient had an aPTTmixing study that did not correct immediately or at 2 hours (56.4 seconds vscontrol 29.7 seconds). Her bleeding time was also abnormally prolonged at 11minutes.

The patient’s factor VIII level was 10%, her von Willebrand factor (vWF)antigen level was 13%, and her vWF ristocetin level was 13% with extremely lowlevels of vW multimers, indicating acquired von Willebrand disease (type III orsevere type I) with an accompanying factor VIII deficiency.

The patient’s dilute Russell’s viper venom test (DRVVT) was normal.Circulating anticoagulant was presumed to be associated with the monoclonalimmunoglobulin (Ig)G-lambda (1,800 mg/dL) discovered on a serum proteinelectrophoresis and immunoprecipitation studies. The patient had a bone marrowbiopsy that showed 10% plasma cells and confirmed diagnosis of monoclonalgammopathy of undetermined significance (MGUS).

Because of the planned surgical procedures, the patient was treated withcorticosteroids. She failed to respond to prednisone at 1 mg/kg for 2 weeks andIV immunoglobulin (1 g/kg/d × 2 infusion) treatment. In light of recent reportsof successful treatment of autoimmune diseases refractory to standard therapy,such as immune thrombocytopenic purpura, with rituximab (Rituxan), we tried thefollowing regimen on this patient: rituximab at 375 mg/m² IV administered weeklyfor 4 weeks for two cycles. After treatment, the patient’s aPTT, bleedingtime, and factor VIII levels normalized; however, she relapsed and wassuccessfully re-treated. Pre- and posttreatment levels are provided in the following table:

CONCLUSION: To the best of our knowledge, this is the first time rituximabhas been used to treat acquired von Willebrand disease secondary toautoantibodies. The response stopped the patient’s clinical bleeding. She hada partial response in her laboratory measurements, with correction of bleedingtime and improved but still prolonged aPTT, while her von Willebrand parametersremained low. She relapsed after a year and a second response was observed byre-treatment with rituximab.

Click here to read Dr. Bruce Cheson's commentary on this abstract.

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Panelists smiling at camera on a blue background.
Panelists smiling at camera on a blue background.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Related Content